Japanese consumer electronics giant Panasonic has officially announced that starting in 2026 it will stop manufacturing its own televisions, transferring production, sales, and marketing to an external partner. The move can be seen as the unofficial “end” of Panasonic-made TVs.
The largest US technology giants are expected to collectively spend around $650 billion this year on artificial intelligence infrastructure and development, according to an analysis by Bridgewater Associates. At the same time, analysts at Goldman Sachs argue that AI spending so far has essentially failed to translate into measurable US GDP growth, raising questions about the efficiency and speed at which these investments convert into real economic gains.
Chinese startup DeepSeek used Nvidia’s most advanced AI chips, which are subject to US export restrictions, to train its latest artificial intelligence model – according to officials from the US administration. The development once again puts the effectiveness of export controls and the pace of China’s AI advancement at the center of debate.
Meta’s director of AI safety and alignment, Summer Yue, accidentally allowed an autonomous artificial intelligence agent to delete her inbox, even though she had explicitly instructed it not to do so. The incident, which she described herself on social media, has become a high-profile example of challenges related to AI safety and control.
Despite growing investment in artificial intelligence and widespread enthusiasm about its potential, many CEOs say AI has not yet translated into measurable gains in productivity or employment, while some experts and public figures argue that mass white-collar layoffs may be closer than expected. Together, these two trends — an apparent “productivity paradox” and mounting labor-market concerns — paint a complex picture of AI’s economic impact.
In recent years, GLP-1–based weight-loss drugs have decisively moved beyond a narrow medical topic and become a mainstream subject of discussion in the US, Europe, and Canada. Explosive demand growth, intensifying competition, and expectations of change driven by patent timelines have turned the search for Ozempic alternatives into a practical question: what should you choose if Ozempic is hard to obtain, too expensive, or poorly tolerated?
The U.S. Department of Defense has been actively lobbying leading artificial-intelligence companies — including OpenAI and Anthropic — to allow their AI tools to be deployed on secret, classified military networks without the standard usage restrictions applied to civilian customers. The move is intended to extend the integration of advanced generative-AI systems across all levels of military operations — including the most sensitive ones.
Microsoft has released a new set of security updates for Windows 10 that fixes 58 software vulnerabilities, including six critical zero-day flaws — meaning vulnerabilities that were actively exploited in attacks before the patches became available. The update is already available, and security specialists stress that installing it as soon as possible is essential to protect computers against system takeover, privilege escalation and other cyber threats.
Danish pharmaceutical company Novo Nordisk has filed a lawsuit against U.S.-based Hims & Hers Health for patent infringement, linked to the company’s attempt to bring to market a cheaper, compounded version of a semaglutide-based weight-loss pill — the key active ingredient in blockbuster products such as Wegovy and Ozempic.
SpaceX is changing the order of its long-term exploration goals and will focus first on building permanent infrastructure on the Moon, postponing its ambitions for Mars to a later stage. The new direction was publicly confirmed by Elon Musk, who explained that the Moon offers a realistic chance to build a self-sustaining base much faster than Mars.